-
Our passion is for life
At SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
-
Defined by the journey
At SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
-
Driven to deliver
At SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
-
Life connects us
At SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, a differentiated, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
© 2026 SynOx Therapeutics